For patients with bowel cancer, screening may extend survival despite late stage diagnosis
the ONA take:
According to a new study published in the British Journal of Cancer, patients with late stage bowel cancer whose disease is diagnosed through screening may have a better prognosis compared with those whose late stage bowel cancer is diagnosed after symptoms develop.
Researchers from the University of Leeds in Leeds, England, and Durham University in Durham, England, identified more than 300 patients diagnosed with bowel cancer through screening and approximately 200 patients that had negative fecal occult blood testing (FOBT) but developed symptoms before their next scheduled test two years later.
The researchers found no difference in overall survival or mortality rates for patients with early stage bowel cancer diagnosed through screening compared with patients diagnosed from symptoms; however, patients with late stage disease diagnosed through screening had a significantly increased survival compared with those diagnosed from symptoms after negative FOBT. The researchers acknowledge the bias created from the lead-time. Because patients' cancers are detected earlier through screening, their lifespan may appear to be extended even though it may not be.
According to the American Cancer Society, bowel or colorectal cancer is the third most common cancer diagnosed in both men and women in the United States.
Late stage bowel cancer who are diagnosed through screening may have a better prognosis.
Although bowel cancer screening usually detects cancer at an earlier stage, new research indicates that when screening detects a late stage cancer patients may be more likely to survive than those whose late stage cancer is only diagnosed after developing symptoms.
The study, published today (Wednesday) in the British Journal of Cancer, follows earlier research from the same team that suggested patients with screen detected bowel cancers could have a better chance of beating the disease because screening generally picks up cancers at an earlier stage when treatment is more likely to be effective.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|